Study Links Maternal Autoantibodies to Preterm Birth
Researchers identify a broad autoantibody signature that appears in pregnancies ending in early delivery.
Updated on Nov. 6, 2026 in Pregnancy
Researchers compared term and preterm pregnancies and identified a maternal autoantibody signature associated with preterm delivery. The signature comprises reactivities to 9,209 peptides from 3,594 proteins.
Why it matters
The findings point to an immune-related pattern that may help explain why some pregnancies end early. Because the signature diverges from term pregnancies as early as the first trimester, it may be relevant to identifying risk well before delivery.
The preterm-associated signature targets proteins involved in hormone signalling, placental angiogenesis, tissue remodelling, HLA molecules, and cytokines, and the breadth of reactivity rises in the weeks before delivery. Women with four or more previous pregnancies showed greater autoantibody reactivity, while whether the link is causal remains unresolved.
The details
The authors also identified autoantibodies targeting IL-1 receptor antagonist (IL-1RA), a protein linked in related work to inflammatory and vascular pathology during pregnancy. The signature is strongest in earlier preterm deliveries, those before 28 weeks.
Timeline
First trimester: the autoreactive signature diverges from term pregnancies.
Weeks preceding preterm delivery: the breadth of autoreactivity increases.
Before 28 weeks: autoantibody reactivity is greater than in later preterm deliveries.
Health Landscape
The work extends earlier research on IL-1RA autoantibodies, which were already associated with inflammatory and vascular pathology in pregnancy. Framing preterm birth as partly immune-driven would broaden how clinicians think about a condition that remains among the leading causes of complications in newborns.
For now the findings are research-stage and do not change prenatal care or testing. Pregnant readers should continue to discuss any preterm-birth risk factors, such as multiple prior pregnancies, with their clinicians.
The takeaway
Autoantibody profiling may eventually offer an early signal of preterm risk, but the current evidence shows association rather than proof of cause. Readers should treat this as an emerging research direction rather than a change to current care.
Further reading
For more on the conditions surrounding early delivery, explore the Pregnancy section.
Source note: This article includes information reported by Nature.
